Navigation Links
VeroScience Late-Breaking Abstract on Cycloset (A Quick Release,Formulation of Bromocriptine Mesylate) Accepted for Poster,Presentation at American Diabetes Association 67th Scientific,Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, and Glycemic Control in Subjects with Type 2 Diabetes Receiving Diet, Oral Hypoglycemic, and/or Insulin Treatment Regimens," will be included in the category of Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications and displayed Saturday, Sunday and Monday, June 23-25, in the General Poster Session in the Exhibit Hall.

VeroScience is also sponsoring a corporate symposium supported by its commercialization partner for Cycloset(TM), S2 Therapeutics, Inc., that will be held in conjunction with the American Diabetes Association's 67th Scientific Sessions. The symposium, entitled "Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes," will be held on Sunday, June 24th from 5:30-7:45 AM at the Hyatt Regency Chicago, Grand F/D South. Registration and breakfast are from 5:00-5:30 AM or you can register in advance at www.veroscience.com/ada2007registration.

Cycloset(TM), an oral, quick-release formulation of bromocriptine is a centrally-acting dopamine D2 receptor agonist that is being studied as a potential therapy in the treatment of type 2 diabetes.

VeroScience is a privately held biotechnology and healthcare product development company with main offices and laboratories in Tiverton, RI. VeroScience has a large patent portfolio tha
'"/>




Page: 1 2

Related medicine technology :

1. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
2. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
5. OXiGENE Abstracts Published in ASCO Program
6. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
7. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
8. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
9. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
10. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
11. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
Post Your Comments:
(Date:10/8/2008)... Incorporated (Nasdaq: VICL ),today is presenting...emonstrating that the company,s Vaxfectin(R) adjuv...based infectious disease vaccines and,peptide-base...D., Vical,s,Senior Vice President of Product Devel...tober 8, at the World Vaccine Congress (Lyon, Fran...
(Date:10/7/2008)... detecting polyps that can be ...7 /- At the American College of,Gastr...ACG 2008), renowned,gastroenterologist Douglas K. ...al clinical study that evaluated the efficacy of t...s designed to improve the ability,of physicians to...
(Date:10/7/2008)...munologic Changes Induced by Glute... Indicates Potential in Treating Inflammatory Bowe...Alba Therapeutics Corporation,presented results fr...College of Gastroenterology (ACG) 2008 Annual Scie... first Phase IIa trial conducted in celiac disease...
(Date:10/7/2008)...Scientific Meeting -, ORLANDO, Fla., Oct. 7 /PRNe.... (formerly Microbia, Inc.) and Forest Laboratorie...tion of results from a Phase,2b study assessing li...th,irritable bowel syndrome with constipation (IBS...ly oral dosing of linaclotide, across a range of,d...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5National Alliance for Healthy Communities Sponsors High Desert Health Summit on Friday October 10th 26673 1National Alliance for Healthy Communities Sponsors High Desert Health Summit on Friday October 10th 26673 2Heart CT Scan Helps Find Coronary Artery Disease 26671 1Heart CT Scan Helps Find Coronary Artery Disease 26671 2ADA Asks Congress to Strengthen Medicaid Oral Health Programs 26669 1ADA Asks Congress to Strengthen Medicaid Oral Health Programs 26669 2ADA Asks Congress to Strengthen Medicaid Oral Health Programs 26669 3Spry Debuts with Inspiration Everywhere 26667 1Spry Debuts with Inspiration Everywhere 26667 2Spry Debuts with Inspiration Everywhere 26667 3
... (ASCP) Contributing Editor , Some form of e...er of most clinical laboratories. A blood cell cou...ess general health, rule out anemia or infection, ...hemotherapy. It is difficult to imagine medical ca...o learn its origins., Early testing of sonar,...
...ovative technology has enabled more and more labor...s office, the central laboratory is hardly threate...that medium and large labs are busier than ever be...ld standard reliability and ability to handle very...d pivotal position in the clinical landscape. , ...
Other Medicine Technology:Hematology Analyzers Simple, Sophisticated Technology Serving All Patients 2Hematology Analyzers Simple, Sophisticated Technology Serving All Patients 3Immunoassay Systems - Your Laboratory Workhorse 2
(Date:10/9/2008).... 9 /PRNewswire/ -- Nature,s Way Holding Company, ...harmaceuticals, a leading,worldwide producer of cl...ent to acquire all outstanding shares of Enzymatic...rolling shareholder of Enzymatic Therapy. The,agre...their signatures and,provides for customary condit...
(Date:10/9/2008)... 9 /PRNewswire/ -- DogChannel.com, the premier,onl...ch of its Dog Medical,Conditions section, where vi...owsing through a list of symptoms., The symptom l... was,compiled by Dog Fancy,s "Ask the Vet" expert...e section contains the 40 most common signs of a,s...
(Date:10/9/2008)...ger patients, study says , , THURSDAY, O...r, regardless of age, seem to benefit from and tol...tudy says. , The finding, published online Oct....e , counters the general perception that older pat... more likely to suffer side effects than younger p...
(Date:10/9/2008)... Volunteers in Medicine is easing the pain of the...the country. , Burlington...ities across the country, 250,000+ retired physici... solution to the healthcare crisis. Volunteers i... to promote and guide the development of a nationa...
Breaking Medicine News(10 mins):Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3Health News:DogChannel.com Launches Online Guide to Dog Medical Conditions 2Health News:Free Clinics Now Providing Healthcare Solutions to the Uninsured 2Health News:Free Clinics Now Providing Healthcare Solutions to the Uninsured 3
...plant surgery has been conducted by Indian doctors...ear-old boy. The surgery took place at the Asha Di...was the donor for the child who was afflicted by a... surgeon Sanjay Govil said that the boy who was bo...
...e stable there are certain conditions under which ... unbounded proteins leading to protein aggregation...responsible for causing neurodegenerative disorder...esearch team from Universitat Autònoma de Barcelon...
...raided on Wednesday doctors and hospitals in the g...estimated Rs 100 million.// Six hospitals in Chenn...ffices and residences of 14 prominent doctors were...ly. About Rs.6 million in cash as well as fixed de...
...ch effort, kin cancer researchers from all over th... to help the world understand what exactly their r...ffort, the international Genomel consortium based ...d of ?7 million. Dermatologist Professor Julia New...
Other Medicine News:
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc.
... The Dual Media Set, different from commonly used ...B) or other specially prepared medium, contains tw...ROTH (OB). For cell expansion, E. coli cells are g...t protein is almost completely repressed. For high...
YET/2 BROTH
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose.
Medicine Products: